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Abstract
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) led to a significant disease
burden and disruptions in health systems. We describe the epidemiology and transmission char-
acteristics of early coronavirus disease 2019 (COVID-19) cases in Bavaria, Germany. Cases were
reverse transcription polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infections,
reported from 20 January−19 March 2020. The incubation period was estimated using travel
history and date of symptom onset. To estimate the serial interval, we identified pairs of
index and secondary cases. By 19 March, 3546 cases were reported. A large proportion
was exposed abroad (38%), causing further local transmission. Median incubation period of
256 cases with exposure abroad was 3.8 days (95%CI: 3.5–4.2). For 95% of infected individuals,
symptom onset occurred within 10.3 days (95%CI: 9.1–11.8) after exposure. The median serial
interval, using 53 pairs, was 3.5 days (95%CI: 3.0–4.2; mean: 3.9, S.D.: 2.2). Travellers returning to
Germany had an important influence on the spread of SARS-CoV-2 infections in Bavaria in
early 2020. Especially in times of low incidence, public health agencies should identify holiday
destinations, and areas with ongoing local transmission, to monitor potential importation of
SARS-CoV-2 infections. Travellers returning from areas with ongoing community transmission
should be advised to quarantine to prevent re-introductions of COVID-19.
Introduction
As of 22 December 2020, 75 129 306 cases of coronavirus disease 2019 (COVID-19) have been
reported worldwide, including 561 617 deaths [1]. COVID-19 is caused by the novel severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2). This virus was identified as the infectious
agent of the initial outbreak of viral pneumonia in Wuhan, China, in early January 2020 [2].
In March 2020, coronavirus disease 2019 (COVID-19) was declared a worldwide pandemic [3].
Since late February 2020, most new cases were reported from outside China, with an
increasing proportion of these reported from the European Union (EU)/European
Economic Area (EEA) countries [4, 5]. The first documented transmission of COVID-19 in
Europe occurred in Bavaria in late January 2020, and comprised a cluster of 16 cases [6, 7].
While the last case of this cluster was reported on 11 February, new cases continued to be
reported on 27 February and onwards.
Epidemiological parameters, such as the incubation period and the serial interval of
SARS-CoV-2, are key factors to characterise the spread of the virus in order to guide interven-
tions, e.g. the duration of quarantine of contact persons, and to quantify the effect of interven-
tions on transmission. Concerted efforts to contain disease spread in the federal state of Bavaria,
Germany, included comprehensive contact tracing and testing of contact persons, resulting in
extensive data on transmission patterns [6, 8]. As additional information was available on poten-
tial exposure intervals and transmission chains for cases affected during the first few weeks of the
spread, we characterised the epidemiology and transmission parameters of 3546 cases of
COVID-19 reported in Bavaria, Germany, between 20 January and 19 March 2020.
Methods
Surveillance
In Germany, notification of SARS-CoV-2 infections was mandatory since 30 January 2020 [9].
A case was defined as a person with a laboratory confirmation by detection of SARS-CoV-2 by
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reverse transcription polymerase chain reaction (RT-PCR) [10].
Initially in Bavaria, most samples were tested at the Public
Health Microbiology (PHM) laboratory of the Bavarian Health
and Food Safety Authority (LGL) [6]. As the epidemic advanced,
additional private, hospital and university laboratories offered
SARS-CoV-2 testing.
For the first 580 cases, the state public health authority main-
tained a dedicated manual line list to record notifications of
SARS-CoV-2 cases in Bavaria, and subsequently switched to
using the standard electronic surveillance system. The manual
line list included additional information received through event
and laboratory reports, as well as contact tracing data from local
health authorities. Information on transmission chains between
some cases was available.
Testing strategy in the German federal state Bavaria (∼13 mil-
lion inhabitants) was as follows: Individuals who had cumulative
face-to-face contact for at least 15 min with a person with a
laboratory-confirmed SARS-CoV-2 infection, or direct contact
with body fluids of a case, were deemed contacts and were eligible
for testing, irrespective of symptoms. Individuals with respiratory
symptoms returning from defined risk areas were also eligible for
testing [11]. Upon identification of persons eligible for testing, a
first upper respiratory sample was taken. Another sample was
taken of contact persons who developed symptoms during a
14-day quarantine and irrespective of signs and symptoms, a
final sample was collected at the end of the quarantine. From 3
March onwards, the final sample was no longer required, and
from 19 March onwards, testing of asymptomatic contact persons
was discontinued.
Individuals who reported travel outside of Bavaria, Germany
up to 28 days before symptoms onset and were presumably
exposed outside of Bavaria, were therefore considered to have
been exposed during travels. Until 19 March, the presumed
exposure of most reported cases in Bavaria could still be linked
to either a stay abroad or contact to a known case, and percentage
of reported symptomatic COVID-19 cases ranged between 40%
and 80% [12]. Meanwhile, we know community transmission
was present in February and early March in some popular travel
destinations [13]. Thus, it is most likely that these cases were
exposed during their travels outside of Bavaria, Germany, thus,
providing a confined window of exposure.
Descriptive epidemiology
We described reported cases in terms of geographic distribution,
as well as symptom status and demographic characteristics. We
defined cases as asymptomatic, if clinical information was avail-
able, and none of the following symptoms was reported: cough-
ing, diarrhoea, dyspnoea, fever, pneumonia, sore throat and
runny nose.
Differences between proportions were tested using either the
Chi-squared test or Fisher’s exact test. For all analyses, we used
the statistical software program R [14]. Visualisations were made
using the ggplot2 package [15]; maps were made using the tmap
package [16] and networks with the igraph package [17].
Incubation period and serial interval
We estimated the incubation period using cases exposed outside
of Bavaria as defined above, who had complete data on both travel
period and day of symptom onset. From reported travel histories
and symptom onset dates, we inferred the earliest and latest point
of exposure, and subsequently the minimum and maximum incu-
bation period of these cases, as has been done previously [18]. To
account for long travel periods, and assuming the earliest point of
exposure to be on 1 February 2020, we corrected earlier points of
exposure to 1 February. For individuals of a family who travelled
together, of whom we presume continuous contact after their tra-
vels, the last potential point of exposure was set equal to their own
day of symptom onset to account for a later point of infection
through an infectious family member. We fitted three parametric
distributions (gamma, log-normal and Weibull) used to describe
incubation periods [18, 19] to the interval data of possible points
of exposure. The parametric distribution with the highest
log-likelihood was reported and also applied to further analysis
using stratified subsets to compare means. We used the icenReg
package to estimate parameters of the fitted distributions [20].
Confidence intervals were obtained using 1000 parametric
bootstrap samples.
To estimate the serial interval, we identified pairs of index and
secondary cases from the manual line list, and included those with
known dates of symptom onset. We selected only those secondary
cases who had a documented exposure to the index case and
where no other potential source of infection was known. We fitted
the gamma, log-normal and Weibull distribution using maximum
likelihood estimations. We compared the fit of these distributions
using the Akaike information criterion (AIC) [21]. Confidence




In total, 3546 cases were reported from 20 January until 19 March
2020. More than half of the cases were male (54%, n = 1904 vs.
46%, n = 1642). The median age was 46 years (IQR: 30–56) and
the mean age was 44 (standard deviation (S.D.): 18.1) years. The
date of symptom onset was available in 2023 cases (57%).
Figure 1 illustrates the number of cases by date of symptom onset.
The largest proportion of all reported cases (23%) were in the
age group from 50 to 60 years and a fifth (21%) were between 40
and 50 years of age. Three percent of reported cases were below
the age of 10 (Table 1). Approximately 20% (518/2620) of
reported cases were asymptomatic: a larger proportion of asymp-
tomatic cases occurred among those 19 years old and younger
(31%), compared with those 20 years of age and older (19%)
(Chi-squared test, P value <0.01). The proportion of asymptom-
atic cases among adults under 60 (18%) and over 60 years of
age (19%) were not significantly different. The case fatality ratio
increased with age, and was highest (31%) among cases 80
years and older.
The largest number of cases were reported from Bavaria’s cap-
ital, the city of Munich (n = 850), followed by the surrounding
Munich county (n = 168) and adjacent Freising county (n = 155).
Development of the incidence per 100 000 population among
cases with known date of symptom onset is illustrated in Figure 2.
Data on travel exposure were available for 1901 (54%) out of
3546 reported cases. Of those, 728 reported travel exposure out-
side of Bavaria (38%). Most cases had travelled to Austria (n =
338), followed by Italy (n = 286) and Spain (n = 18). Up until 8
March, most cases with exposure abroad had returned from
Italy (66%), whereas from 9 March onwards, most cases had
returned from Austria (64%, Fig. 1).
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Incubation period and serial interval
We used records of 256 cases with exposure abroad and complete
data on travel history, who returned up to 28 days before symptom
onset and reported at least one defined symptom, to estimate the
incubation period. Among the included cases were individuals
who had reported travel to the German federal state North
Rhine-Westphalia (n = 2), Austria (n = 136), Italy (n = 106), Spain
(n = 10) and Iran (n = 2) (Sup. Fig. 1). The largest log likelihood
was observed when fitting the log-normal distribution. Using the
log-normal distribution, the median incubation period of
SARS-CoV-2 was 3.8 days (95%CI: 3.5–4.2, Fig. 3). For 95% of
infected symptomatic individuals, symptom onset occurred within
10.3 days of exposure (95%CI: 9.1–11.8). The mean of the log-
normal distribution was 4.6 days a standard deviation of 3.0 days.
We observed a difference in the incubation period between
cases exposed in Italy and Austria (Sup. Fig. 2). Cases related to
travels to Italy had a mean incubation period of 5.6 days (S.D.:
3.8) and a median of 4.6 days (95%CI: 4.0–5.3), whereas
Bavarian cases who were exposed in Austria had a mean of 3.7
days (S.D.: 2.1) and a median incubation period of 3.2 days
(95%CI: 2.9–3.6). Cases who were exposed in Italy had on average
a longer duration of stay abroad than those who were exposed in
Austria (6 vs. 4 days), an earlier date of symptom onset and a dif-
ferent age distribution (Sup. Fig. 3A–C). Twelve per cent of the
cases who got infected in Italy were below 20 years of age, while
this was 1% of those exposed in Austria and 17% of the cases asso-
ciated with travels to Austria were between 30 and 40 years of age
vs. 8% of cases related to travels to Italy (Sup. Fig. 3A–C). We strati-
fied incubation periods by duration of stay abroad, date of symp-
tom onset and age (Sup. Fig. 3D–F). After stratifying by duration
of stay abroad, the difference between the estimates for Italy and
Austria became smaller for a duration of 4 days and disappeared
for a duration of 6 days (Sup. Fig. 4).
Out of 91 pairs of index and secondary cases, comprising 122
individuals, 53 pairs had sufficient information to estimate the
serial interval. Among these pairs, no transmission was observed
from children of 10 years and younger (Sup. Fig. 5). The youngest
index patient was a 12-year old, who infected two teenagers. The
average difference between symptom onset in these 53 pairs was
3.9 days, and ranged from 1 to 9 days. We observed the lowest
AIC when fitting the gamma distribution to the data. We
estimated that the median serial interval was 3.5 days (95%CI:
3.0–4.1, Fig. 4). In 95% of pairs, the serial interval was less than
8.0 days (95%CI: 6.6–9.4). The mean serial interval was 3.9 days
with a standard deviation of 2.2 days.
Discussion
Exposure to a case from China at the end of January 2020 led to
an outbreak of 16 cases in Bavaria that was successfully contained
[6]. The testing policy, consisting of testing symptomatic indivi-
duals returning from risk areas as well as all contact persons, ini-
tially regardless of the presence of symptoms, ensured
identification of COVID-19 cases and transmission chains. The
first reported COVID-19 cases comprised numerous cases who
visited popular travel destinations during a state-wide holiday,
and were exposed to community transmission during their travels.
These cases drove the initial spread that rapidly led to an expo-
nential increase of COVID-19 cases, reaching 3546 reported
cases by 19 March.
Slightly below most estimates of the incubation period [22–26]
of around 5 days, we observed a mean incubation period of 4.6
days, and 95% of cases developed symptoms within 11 days. A
surprising difference was noted in the incubation periods of
cases arising from travel to Italy and Austria. Although some of
the difference was explained by the duration of travel, the mean
Fig. 1. Number of reported COVID-19 cases by date of symptom onset (n = 2023) and by place of exposure in Bavaria, Germany, of cases reported between 20
January and 19 March 2020.
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incubation period for cases with exposure in Italy was still higher
with the same duration of stay. We may not have been able to
identify all families among travellers returning from Italy.
Family groups were more common among travellers from Italy,
and an unidentified continued exposure to SARS-CoV-2 after a
stay abroad would overestimate the incubation period. Travellers
from Austria might have been more aware of a possible risk of
COVID-19 and thus more attentive to onset of symptoms, as
those travellers returned to Bavaria later in the outbreak, and
Austria was declared a risk area quicker than some parts of
Italy. Finally, a difference in the incubation periods could also
be due to differing types of contact or levels of exposure, related
to holiday activities in each country [27–29].
Out of 53 pairs of index and secondary cases, we estimated a
mean serial interval of 3.9 days. This corresponds with two
other studies [30, 31], but is lower than in a systematic review
[32]. The serial interval is also dependent on the effectiveness
of interventions, such as timing of isolation, and thus, may be
changing over time [32, 33]. The mean serial interval is almost
one day shorter than the mean overall incubation period (4.6
days) but equal to the mean incubation period for cases coming
from Austria (3.7 days). A serial interval shorter than the incuba-
tion period suggests that cases may be infectious before the first
symptoms are apparent [34]. Our data imply that infectiousness
of SARS-CoV-2 peaks around the time of symptom onset.
A strength of our study is the extensive contact tracing by local
health authorities, resulting in a high completeness of reporting
[12]. This is underlined by the low average age, the high percent-
age of asymptomatic cases and the low case fatality ratio for
reported cases compared with the epidemiological situation in
other European countries during the first wave in spring of
2020 [35, 36]. The mean age of 44 was lower than reported
from other countries during the early phase of the outbreak
[37, 38]. The overall proportion of asymptomatic cases was
20%. This proportion is comparable to a community-based esti-
mate (22%) based on the number of clinical manifestations
among sero-positive individuals and a modelling study (18%),
where the symptom status was elucidated from COVID-19 cases
on board of a cruise ship. The populations under observation in
these studies were, on average, older than our study population
[39, 40]. The proportion of symptomatic cases was however
much higher than estimated by Davies et al., who modelled that
the proportion of symptomatic infections rose from 21% (credible
interval 12–31%) in 10- to 19-year-olds to 69% (credible interval
57–82%) in older adults [41]. And, as underlined by our findings,
asymptomatic infections were more present among younger age
groups [42].
An inherent caveat of using contact tracing data for the pur-
pose of estimating epidemiological parameters is that many
cases were found at an earlier stage, compared with passive sur-
veillance. Asymptomatic infections at the point of sampling
may have remained asymptomatic, but some may also have devel-
oped symptoms at a later stage that remained unregistered. This
selection bias may have shortened our interval estimates and
may have increased the proportion of asymptomatic cases in
our study.
In both the assessment of the proportion of (a)symptomatic
cases and the proportion of cases related to travel, we have chosen
to omit cases with a missing value. Some asymptomatic infections
may have been classified as cases with missing data on symptom
status, as there is no specific data-entry possibility for an asymp-
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symptoms other than coughing, diarrhoea, dyspnoea, fever, pneu-
monia, sore throat or runny nose might have been classified as an
asymptomatic case. Besides the potential limitations mentioned,
symptomatic persons with a SARS-CoV-2 infection have a higher
likelihood of being tested and thus reported. Looking at
notification data may therefore overestimate the proportion of
symptomatic cases. The proportion of cases with exposure abroad
was also subject to cases with missing values. It may be that cases
without data on place of exposure were largely exposed in Bavaria
(proportion of cases with exposure abroad over all reported cases
Fig. 2. Geographic distribution of COVID-19 cases reported from 20 January to 19 March 2020 in Bavaria, Germany. Map A depicts the cumulative incidence of
COVID-19 cases with known date of symptom onset up to 5 February (exclusively showing the first previously described cluster [6]), map B up to 23 February
2020, map C up to 2 March 2020, map D up to 10 March 2020 and map E up to 19 March 2020.
Fig. 3. Estimated incubation period of SARS-CoV-2 using the log-
normal with 95%CI (blue) parametric distribution and the non-
parametric estimate with 95%CI in grey (Kaplan−Meier plot).
Epidemiology and Infection 5
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was 21%). In addition, during the initial outbreak phase testing was
focused only on persons with known exposure (contact to a case or
travels to risk area) [11]. These two points might have led to an
overestimation of the proportion of cases with exposure abroad.
A further caveat of our study concerns the estimation of the
incubation period. Cases may have been infected before or after
their stay abroad. Some of the cases, especially towards the end
of the study period, had a higher chance of being infected prior
to their stay abroad than those at the beginning of the study per-
iod due to the local rise in cases. However, given the low incidence
in late February and early March in Bavaria, Germany [43–45],
the high incidence in the visited countries, similar incubation per-
iods among cases stratified by date of symptom onset (Fig. S3E),
and the relatively large sample size in the estimation of the incu-
bation period, we expect that an inconsiderable fraction of the
cases was infected prior to their stay abroad.
Conclusion
The analysis of the epidemiology and transmission characteristics
of the first COVID-19 cases in Bavaria, Germany, contributes to a
further understanding of the novel SARS-CoV-2. In the early
weeks of the pandemic, an important proportion of reported
cases in Bavaria was attributed to travel outside the region, leading
to rapid local transmission. This underlines the importance of
continuing efforts in times of low incidence to identify returning
travellers who may have been exposed in locations with commu-
nity transmission, and to quarantine returnees. Duration of quar-
antine can be deduced from the incubation period. Popular
holiday destinations change from winter to summer seasons, so
public health authorities should remain abreast of all areas
where SARS-CoV-2 infections are continuing or increasing, in
order to apply these protection measures and inform the travel-
ling public. These measures are warranted to prevent future
numerous importations of SARS-CoV-2, leading to sudden
large outbreaks.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268821000510.
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